Evaxion A/S (EVAX) Expected to Post Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX) is expected to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Evaxion A/S to announce earnings of ($0.01) per share and revenue of $6.70 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Evaxion A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, analysts expect Evaxion A/S to post $-0 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Evaxion A/S Price Performance

EVAX stock opened at $2.98 on Thursday. The firm has a 50 day moving average of $3.28 and a 200-day moving average of $3.63. The firm has a market capitalization of $24.85 million, a P/E ratio of -2.03 and a beta of 0.29. Evaxion A/S has a 12 month low of $2.52 and a 12 month high of $12.15. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Evaxion A/S stock. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,194 shares of the company’s stock, valued at approximately $72,000. SmartHarvest Portfolios LLC owned approximately 0.18% of Evaxion A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on EVAX shares. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Friday, April 24th. Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.